Ranolazine Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 500 mg and 1000 mg
Reference Brands: Ranexa(US & EU)
Category:
Heart Disorder
Ranolazine inhibits late sodium current in cardiac cells, reducing calcium overload and improving myocardial efficiency. It decreases angina episodes, enhances exercise tolerance, and reduces oxygen demand. Benefits include better symptom control, improved cardiac function, and increased quality of life for patients with chronic angina.
Ranolazine tablet is available in Tablet
and strengths such as 500 mg and 1000 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ranolazine tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ranolazine tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ranolazine tablets, marketed as Ranexa, are approved in the US by the FDA and in the EU via EMA for the treatment of chronic angina. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper regional adherence supports timely approval, safe medication use, and global availability, helping millions manage angina and improve quality of life worldwide effectively.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing